Trial results for upadacitinib (Rinvoq) in rheumatoid arthritis were published on 2018-01-01. The SELECT-BEYOND study evaluated the safety and efficacy of upadacitinib in patients with active rheumatoid arthritis who had not responded adequately to prior biologic disease-modifying anti-rheumatic drugs (bDMARDs). This publication represents a significant step in understanding the drug's potential in a challenging patient population.
Background
Upadacitinib is a therapeutic agent investigated for the treatment of rheumatoid arthritis. Rheumatoid arthritis is a chronic, systemic autoimmune disease characterized by inflammation of the joints, leading to pain, swelling, stiffness, and potential joint damage. Patients whose disease remains active despite treatment with biologic disease-modifying anti-rheumatic drugs (bDMARDs) represent a population with significant unmet medical needs, often requiring alternative treatment strategies. The search for effective treatments for this refractory patient group is ongoing.
Trial design
The SELECT-BEYOND study was designed as a pivotal trial to compare upadacitinib against placebo. It enrolled adult patients diagnosed with rheumatoid arthritis who were already on stable doses of conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) but had demonstrated an inadequate response to at least one prior biologic DMARD. The primary objectives of the study were to assess the safety and efficacy of upadacitinib in this specific, difficult-to-treat patient group. The trial aimed to provide comprehensive data on how upadacitinib performs in terms of disease activity reduction and overall tolerability when existing biologic options have failed, thereby addressing a critical gap in treatment options.
What this means
The publication of the SELECT-BEYOND trial results is important for clinicians and patients dealing with rheumatoid arthritis that is refractory to biologic therapies. While specific outcome measurements are not detailed in this summary, the focus on "safety and efficacy" in the publication's headline indicates that the study provided data supporting the drug's profile in this context. For patients who have exhausted conventional and biologic treatment options, the availability of new data for agents like upadacitinib offers potential new therapeutic avenues. This publication contributes to the growing body of evidence for upadacitinib as a treatment option for active rheumatoid arthritis and informs clinical decision-making for patients with difficult-to-treat disease.
Source
The information regarding the SELECT-BEYOND study, evaluating upadacitinib, was published on 2018-01-01. The source document, titled "Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND)", is referenced on PubMed, accessible via pubmed.ncbi.nlm.nih.gov.